Roche Holding AG (RHHBF)
| Market Cap | 289.56B |
| Revenue (ttm) | 79.83B |
| Net Income (ttm) | 11.86B |
| Shares Out | n/a |
| EPS (ttm) | 14.77 |
| PE Ratio | 24.42 |
| Forward PE | 14.15 |
| Dividend | 10.97 (3.11%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 104 |
| Average Volume | 80 |
| Open | 368.13 |
| Previous Close | 346.04 |
| Day's Range | 336.83 - 368.88 |
| 52-Week Range | 280.85 - 380.00 |
| Beta | 0.18 |
| RSI | 55.58 |
| Earnings Date | Oct 20, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Roche Holding AG (RHHBY) Gains CE-IVDR Approval for VENTANA HER2 (4B5) Test | RHHBY stock news
Roche Holding AG (RHHBY) Gains CE-IVDR Approval for VENTANA HER2 (4B5) Test | RHHBY stock news
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or ...
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or âwetâ age-related macular degeneration (nAMD) | RHHBY Stock News
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify ...
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients | RHHBY Stock News
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients
The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The V...
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 05 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricimab),1,2 presented at the 25th Euretina Congress in Pa...
New Data for Genentech's Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricim...
Roche gets EU CE mark for its Port Delivery platform containing Susvimo
Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)
Basel, 04 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the EU CE mark for its Port Delivery Platform containing Susvimo, which will now be known as Contivue...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Three Dividend Funds with Foreign Flair
This month's trio includes an unofficial dividend aristocrat.
Alnylam (ALNY) Advances with Roche on Phase 3 Cardiovascular Trial for Zilebesiran
Alnylam (ALNY) Advances with Roche on Phase 3 Cardiovascular Trial for Zilebesiran
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for ...
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension | RHHBY Stock News
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardio...
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Basel, 30 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ability ...
Analog Devices Chair & CEO Trades $5.09M In Company Stock
It was reported on August 28, that VINCENT ROCHE , Chair & CEO at Analog Devices (NASDAQ: ADI) executed a significant insider sell, according to an SEC filing. What Happened: ROCHE's recent Form 4 fi...
Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
Basel, 25 August 2025 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant d...
Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest U.S. manufacturing site in Holly Springs, North Carolina. Th...
“Walk in My Shoes” Spotlights the Invisible Struggles of People Living with Multiple Sclerosis (MS) – a Public Health Awareness Initiative by Roche in Collaboration with Multiple Sclerosis Society of India (MSSI)
Roche Pharma India, in collaboration with the Multiple Sclerosis Society of India (MSSI) presents Walk In My Shoes – a public health awareness initiative to highlight the often invisible struggles of ...
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 18, 2025 (GLOBE NEWSWIRE) -- North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence of vision-threatening di...
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free surviva...
Pennsylvania Rep. Daniel Meuser Sold Up to $1.50M Worth of NVIDIA Stock
A August filing shows that Representative Daniel Meuser reported a sale in NVIDIA (NASDAQ: NVDA), valued between $750,002 and $1,500,000. The transaction date is listed as October 1, 2024, with the r...
Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma
EPALINGES, Switzerland--(BUSINESS WIRE)-- #HCC--Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma.
Roche, Novartis due to meet Swiss govt. amid Trump’s tariff threats: Reuters
Swiss government to meet pharma firms to discuss US tariffs
The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower their prices, as Switzerland seeks to negotiate down a new 39% tariff on it...
Swiss Government Engages Roche and Novartis on U.S. Tariff Impact
Swiss Government Engages Roche and Novartis on U.S. Tariff Impact